{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:46:59Z","timestamp":1787676419320,"version":"build-2784847793"},"reference-count":102,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lodz, Department of Social Medicine","award":["503\/6-029-01\/503-61-001"],"award-info":[{"award-number":["503\/6-029-01\/503-61-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Osteonecrosis is a debilitating condition characterized by the loss of blood supply to the bones, leading to bone death. This condition can impact various bones, including the jaw, which significantly affects patients\u2019 quality of life by causing difficulties in swallowing, feeding, chewing, and speaking, along with swollen, painful mucous membranes and chronic sinusitis. Osteonecrosis can arise due to treatment with antiresorptive drugs. However, there is a growing number of reports of osteonecrosis following novel targeted anti-cancer treatments, such as tyrosine kinase inhibitors (TKIs) and biological therapies. The pathogenesis of osteonecrosis is linked to the side effects of the antiangiogenic mechanisms of these medications, leading to a disrupted blood flow. Our review aims to examine recent insights into osteonecrosis triggered by new anti-cancer drugs. Most reports focus on the osteonecrosis of the jaw (ONJ); however, we discovered that some authors have described cases of osteonecrosis affecting the femoral head or elbow following novel anti-cancer treatments. Prevention is a key component in managing osteonecrosis. Therefore, a comprehensive risk assessment should always be performed before and during anti-cancer therapy.<\/jats:p>","DOI":"10.3390\/jcm13071889","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:32:36Z","timestamp":1711369956000},"page":"1889","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Exploring the Impact of Novel Anti-Cancer Therapies on Jaw Osteonecrosis and Other Bones: A Comprehensive Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5542-9988","authenticated-orcid":false,"given":"Wojciech","family":"Konarski","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Ciechan\u00f3w Hospital, 06-400 Ciechan\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1376-2966","authenticated-orcid":false,"given":"Tomasz","family":"Pobo\u017cy","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Ciechan\u00f3w Hospital, 06-400 Ciechan\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"Konarska","sequence":"additional","affiliation":[{"name":"Medical Rehabilitation Center, Sobieskiego 47D, 05-120 Legionowo, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0239-1637","authenticated-orcid":false,"given":"Andrzej","family":"\u015aliwczy\u0144ski","sequence":"additional","affiliation":[{"name":"Social Medicine, Department of Social and Preventive Medicine, Medical University of Lodz, 90-647 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ireneusz","family":"Kotela","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery and Traumatology, Central Research Hospital of Ministry of Interior, Wo\u0142oska 137, 02-507 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3435-9658","authenticated-orcid":false,"given":"Jan","family":"Krakowiak","sequence":"additional","affiliation":[{"name":"Social Medicine, Department of Social and Preventive Medicine, Medical University of Lodz, 90-647 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Konarski, W., Pobo\u017cy, T., \u015aliwczy\u0144ski, A., Kotela, I., Krakowiak, J., Hordowicz, M., and Kotela, A. (2022). Avascular Necrosis of Femoral Head-Overview and Current State of the Art. Int. J. Environ. Res. Public. Health, 19.","DOI":"10.3390\/ijerph19127348"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lon\u010dar Brzak, B., Horvat Aleksijevi\u0107, L., Vindi\u0161, E., Kordi\u0107, I., Grani\u0107, M., Vidovi\u0107 Juras, D., and Andabak Rogulj, A. (2023). Osteonecrosis of the Jaw. Dent. J., 11.","DOI":"10.3390\/dj11010023"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Konarski, W., Pobo\u017cy, T., Kotela, A., \u015aliwczy\u0144ski, A., Kotela, I., Hordowicz, M., and Krakowiak, J. (2022). The Risk of Avascular Necrosis Following the Stabilization of Femoral Neck Fractures: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph191610050"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00256-008-0549-x","article-title":"Osteonecrosis of the jaw","volume":"38","author":"Reid","year":"2009","journal-title":"Skelet. Radiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"key":"ref_6","first-page":"6944","article-title":"Medication-related Osteonecrosis of the Jaw: A Review","volume":"12","author":"AlDhalaan","year":"2020","journal-title":"Cureus"},{"key":"ref_7","first-page":"36","article-title":"Bisphosphonate-related osteonecrosis of the jaws","volume":"27","author":"Yeo","year":"2005","journal-title":"Singap. Dent. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jobcr.2024.01.014","article-title":"Geranylgeraniol (GGOH), incorporated into a bone cement pellet promotes osteoclast function and healing in a model of medication-related osteonecrosis of the jaw","volume":"14","author":"Feldman","year":"2024","journal-title":"J. Oral Biol. Craniofacial Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.4317\/medoral.23191","article-title":"Review and update on drugs related to the development of osteonecrosis of the jaw","volume":"25","author":"Eguia","year":"2020","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/s41415-020-1642-3","article-title":"Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: A review of the literature","volume":"228","author":"Kanwar","year":"2020","journal-title":"Br. Dent. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","article-title":"Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases","volume":"69","author":"Otto","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J. Clin. Densitom."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kojima, Y., Soutome, S., Otsuru, M., Hayashida, S., Sakamoto, Y., Sawada, S., and Umeda, M. (2022). Factors Exacerbating Clinical Symptoms and CT Findings in Patients with Medication-Related Osteonecrosis of the Jaw Receiving Conservative Therapy: A Multicenter Retrospective Study of 53 Cases. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19137854"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00520-017-4003-2","article-title":"A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer","volume":"26","author":"Schiodt","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.bjoms.2017.06.014","article-title":"Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: Conservative treatment is effective up to stage 2","volume":"55","author":"Coropciuc","year":"2017","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_16","unstructured":"Thomson, R.J., Moshirfar, M., and Ronquillo, Y. (2024). StatPearls, StatPearls Publishing LLC. StatPearls Publishing Copyright \u00a9 2024."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001\u20132020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Pottier, C., Fresnais, M., Gilon, M., J\u00e9rusalem, G., Longuesp\u00e9e, R., and Sounni, N.E. (2020). Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. Cancers, 12.","DOI":"10.3390\/cancers12030731"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management","volume":"8","author":"Sharma","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1535-7163.MCT-05-0503","article-title":"Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1\u03b1 activity and vascular endothelial growth factor expression in small cell lung cancer cells","volume":"5","author":"Litz","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.bjc.6603366","article-title":"Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-\u03b2 and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation","volume":"95","author":"Vlahovic","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_22","first-page":"6621937","article-title":"Medication-Related Osteonecrosis of the Jaw Spontaneously Occurred in a Patient with Chronic Myelogenous Leukemia Only by Imatinib: A Report of a Rare Case","volume":"2021","author":"Yamagata","year":"2021","journal-title":"Case Rep. Dent."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): A prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e7611","DOI":"10.1002\/ccr3.7611","article-title":"Imatinib associated temporal bone osteonecrosis","volume":"11","author":"McKenna","year":"2023","journal-title":"Clin. Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.oooo.2020.10.005","article-title":"Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: A rare case report","volume":"131","author":"Gupta","year":"2021","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5125\/jkaoms.2017.43.2.120","article-title":"A rare case of osteonecrosis of the jaw related to imatinib","volume":"43","author":"Viviano","year":"2017","journal-title":"J. Korean Assoc. Oral Maxillofac. Surg."},{"key":"ref_27","first-page":"29","article-title":"Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib\u2014A case report with clinical implications","volume":"4","author":"Razis","year":"2013","journal-title":"Forum Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.oooo.2017.10.010","article-title":"Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort","volume":"125","author":"Nielsen","year":"2018","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.4317\/jced.58323","article-title":"Photobiomodulation laser therapy in a Lenvatinib-related osteonecrosis of the jaw: A case report","volume":"13","author":"Monteiro","year":"2021","journal-title":"J. Clin. Exp. Dent."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.ijom.2019.07.010","article-title":"Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib","volume":"48","author":"Mauceri","year":"2019","journal-title":"Int. J. Oral. Maxillofac. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhang, X.-Y., Zhang, Y.-K., Wang, Y.-J., Gupta, P., Zeng, L., Xu, M., Wang, X.-Q., Yang, D.-H., and Chen, Z.-S. (2016). Osimertinib (AZD9291), a mutant-selective EGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Molecules, 21.","DOI":"10.3390\/molecules21091236"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.7150\/jca.29933","article-title":"Cytochalasin H inhibits angiogenesis via the suppression of HIF-1\u03b1 protein accumulation and VEGF expression through PI3K\/AKT\/P70S6K and ERK1\/2 signaling pathways in non-small cell lung cancer cells","volume":"10","author":"Ma","year":"2019","journal-title":"J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"947947","DOI":"10.3389\/fphar.2022.947947","article-title":"Osimertinib: Another medication related to osteonecrosis of the jaws? A case report and literature review","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/ijc.32399","article-title":"Osimertinib and jaw osteonecrosis? A case report","volume":"145","author":"Subramanian","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s40618-021-01634-0","article-title":"Osteonecrosis of the jaw: A rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates","volume":"44","author":"Lorusso","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.5301\/tj.5000504","article-title":"Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma","volume":"102","author":"Garuti","year":"2016","journal-title":"Tumori"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1200\/JCO.2009.23.4252","article-title":"Sorafenib-induced bilateral osteonecrosis of femoral heads","volume":"28","author":"Guillet","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Guirguis, R.H., Tan, L.P., Hicks, R.M., Hasan, A., Duong, T.D., Hu, X., Hng, J.Y.S., Hadi, M.H., Owuama, H.C., and Matthyssen, T. (2023). In Vitro Cytotoxicity of Antiresorptive and Antiangiogenic Compounds on Oral Tissues Contributing to MRONJ: Systematic Review. Biomolecules, 13.","DOI":"10.3390\/biom13060973"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/01945998211071022","article-title":"Sunitinib-Related Osteonecrosis of the External Auditory Canal: Case Report","volume":"167","author":"Eguia","year":"2022","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_41","first-page":"323","article-title":"Recurrent submandibular fistula after Sunitinib treatment in a patient with renal cell carcinoma: A case report","volume":"96","author":"Golu","year":"2023","journal-title":"Med. Pharm. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/jrpp.JRPP_17_36","article-title":"Osteonecrosis of the Jaws in Patient Received Bisphosphonates and Sunitinib Separately: A Case Report","volume":"6","author":"Ashrafi","year":"2017","journal-title":"J. Res. Pharm. Pract."},{"key":"ref_43","first-page":"952","article-title":"Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: Two case reports","volume":"16","author":"Agrillo","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","article-title":"Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications","volume":"113","author":"Migkou","year":"2012","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib related osteonecrosis of jaw: A case report","volume":"113","author":"Fleissig","year":"2012","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: Presentation of three cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000313680","article-title":"Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib","volume":"33","author":"Bozas","year":"2010","journal-title":"Onkologie"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.4317\/medoral.22858","article-title":"Osteonecrosis of the jaws produced by sunitinib: A systematic review","volume":"24","author":"Vallina","year":"2019","journal-title":"Med. Oral Patol. Oral Cir. Bucal"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/curroncol31010016","article-title":"Relationship between Medication-Related Osteonecrosis of the Jaw and CDK4\/6 Inhibitors in Breast Cancer","volume":"31","author":"Pancorbo","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Marcian\u00f2, A., Guzzo, G.M., Peditto, M., Picone, A., and Oteri, G. (2020). Medication-Related Osteonecrosis of the Jaws and CDK4\/6 Inhibitors: A Recent Association. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17249509"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1177\/10781552231165434","article-title":"Osteonecrosis of the jaw under palbociclib: A case series description","volume":"29","author":"Yosofi","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/10781552221102370","article-title":"Avascular necrosis during alectinib treatment: Case report","volume":"29","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10006-020-00931-x","article-title":"Bosutinib-induced osteonecrosis of the jaw in a patient with chronic myeloid leukemia: A case report","volume":"25","author":"Myoken","year":"2021","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.jcot.2017.11.015","article-title":"Nilotinib induced avascular necrosis of femoral head in an adult chronic myeloid leukemia patient","volume":"9","author":"Thekkudan","year":"2018","journal-title":"J. Clin. Orthop. Trauma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/j.oooo.2017.08.003","article-title":"Axitinib-related osteonecrosis of the jaw","volume":"124","author":"Patel","year":"2017","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Papadopoulou, E., Vardas, E., Tziveleka, S., Georgaki, M., Kouri, M., Katoumas, K., Piperi, E., and Nikitakis, N.G. (2022). Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib-Report of Three Cases. Dent. J., 10.","DOI":"10.3390\/dj10120232"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"djw002","DOI":"10.1093\/jnci\/djw002","article-title":"Regorafenib Also Can Cause Osteonecrosis of the Jaw","volume":"108","author":"Antonuzzo","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"djw155","DOI":"10.1093\/jnci\/djw155","article-title":"RE: Regorafenib Also Can Cause Osteonecrosis of the Jaw","volume":"108","author":"Fusco","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/adj.12254","article-title":"Osteonecrosis of the jaw in a patient receiving cabozantinib","volume":"60","author":"Marino","year":"2015","journal-title":"Aust. Dent. J."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zahavi, D., and Weiner, L. (2020). Monoclonal Antibodies in Cancer Therapy. Antibodies, 9.","DOI":"10.3390\/antib9030034"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"B\u00f6hm, R., von Hehn, L., Herdegen, T., Klein, H.-J., Bruhn, O., Petri, H., and H\u00f6cker, J. (2016). OpenVigil FDA\u2013inspection of US American adverse drug events pharmacovigilance data and novel clinical applications. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157753"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s12967-023-04482-z","article-title":"Osteonecrosis of the jaw induced by immune checkpoint inhibitors: An urgent need for attention","volume":"21","author":"Li","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/039463201202500328","article-title":"Osteonecrosis of the jaws and bevacizumab therapy: A case report","volume":"25","author":"Bandelloni","year":"2012","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"bcr2012007284","DOI":"10.1136\/bcr-2012-007284","article-title":"Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process","volume":"2012","author":"Bettini","year":"2012","journal-title":"BMJ Case Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1200\/JCO.2012.43.6733","article-title":"Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors","volume":"31","author":"Fangusaro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10006-012-0379-9","article-title":"Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab","volume":"17","author":"Pakosch","year":"2013","journal-title":"Oral Maxillofac. Surg."},{"key":"ref_70","first-page":"655","article-title":"A case of osteonecrosis of the jaw during treatment by bevacizumab for sigmoid colon cancer","volume":"110","author":"Sato","year":"2013","journal-title":"Jpn. J. Gastro-Enterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy","volume":"115","author":"Dias","year":"2013","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Erovigni, F., Gambino, A., Cabras, M., Fasciolo, A., Bianchi, S.D., Bellini, E., and Fusco, V. (2016). Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. Dent. J., 4.","DOI":"10.3390\/dj4040039"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.21873\/invivo.11358","article-title":"Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study","volume":"32","author":"Yamaguchi","year":"2018","journal-title":"Vivo"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"omz040","DOI":"10.1093\/omcr\/omz040","article-title":"Bevacizumab-associated osteonecrosis of the femur and tibia","volume":"2019","author":"Oliveira","year":"2019","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40729-019-0188-0","article-title":"A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants","volume":"5","author":"Maluf","year":"2019","journal-title":"Int. J. Implant. Dent."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1563\/aaid-joi-D-21-00155","article-title":"Bevacizumab-Associated Implant Presence-Triggered Osteonecrosis: A Case Report and Literature Review","volume":"48","author":"Ueda","year":"2022","journal-title":"J. Oral Implantol."},{"key":"ref_77","first-page":"1928","article-title":"Half-dose bevacizumab experience in relapsed ovarian cancer patients in Turkey due to formal regulations: Similar effectiveness with lower rate of hypertension","volume":"25","author":"Kose","year":"2020","journal-title":"J BUON"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s10637-010-9406-6","article-title":"Avascular necrosis of the femoral head: A rare class-effect of anti-VEGF agents","volume":"29","author":"Mir","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1097\/JTO.0b013e31822e726f","article-title":"Osteonecrosis of the humeral head in a patient with non-small cell lung cancer receiving bevacizumab","volume":"6","author":"Koczywas","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit","volume":"48","author":"Er","year":"2012","journal-title":"Oral Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2214\/AJR.12.9049","article-title":"Complications of targeted drug therapies for solid malignancies: Manifestations and mechanisms","volume":"200","author":"Abramson","year":"2013","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.bjoms.2023.08.241","article-title":"Pembrolizumab related osteonecrosis of the jaw","volume":"61","author":"Patel","year":"2023","journal-title":"Br. J. Oral Maxillofac. Surg."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jormas.2020.05.001","article-title":"Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab","volume":"121","author":"Decaux","year":"2020","journal-title":"J. Stomatol. Oral Maxillofac. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.oooo.2022.12.013","article-title":"Osteonecrosis of the jaw associated with pembrolizumab","volume":"136","author":"Pennings","year":"2023","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: A systematic review","volume":"27","author":"Kouri","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"104874","DOI":"10.1016\/j.oraloncology.2020.104874","article-title":"Osteonecrosis of the jaw in a metastatic lung cancer patient with bone metastases undergoing pembrolizumab + denosumab combination therapy: Case report and literature review","volume":"111","author":"Myoken","year":"2020","journal-title":"Oral Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.oraloncology.2015.08.014","article-title":"Osteonecrosis of the jaw a new complication related to Ipilimumab","volume":"51","author":"Owosho","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ccr3.3418","article-title":"New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy","volume":"9","author":"Guida","year":"2021","journal-title":"Clin. Case Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7150\/jca.17144","article-title":"Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor","volume":"8","author":"Guo","year":"2017","journal-title":"J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/imt-2020-0108","article-title":"Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: A case report","volume":"12","author":"Pundole","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00003495-200666040-00005","article-title":"Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer","volume":"66","author":"Plosker","year":"2006","journal-title":"Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2165\/00003495-200262010-00008","article-title":"Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2","volume":"62","author":"McKeage","year":"2002","journal-title":"Drugs"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1097\/MD.0000000000000671","article-title":"Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?","volume":"94","author":"Pilanci","year":"2015","journal-title":"Medicine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/adj.12723","article-title":"Osteonecrosis of the jaw in an anti-resorptive na\u00efve patient taking trastuzumab and pertuzumab: Case report","volume":"65","author":"Manzie","year":"2020","journal-title":"Aust. Dent. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","article-title":"Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2","volume":"28","author":"Spratlin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"105660","DOI":"10.1016\/j.oraloncology.2021.105660","article-title":"Ramucirumab-related osteonecrosis of the jaw","volume":"125","author":"Singh","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_102","first-page":"8881749","article-title":"Delayed Healing of Tooth Extraction Sockets with Ramucirumab Use","volume":"2020","author":"Iijima","year":"2020","journal-title":"Case Rep. Dent."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/7\/1889\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:07Z","timestamp":1760105887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/7\/1889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":102,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["jcm13071889"],"URL":"https:\/\/doi.org\/10.3390\/jcm13071889","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]}}}